GSK snags first-in-class FDA nod for Rukobia to treat HIV patients who have few options

Thursday, the FDA approved GlaxoSmithKline subsidiary ViiV Healthcare’s Rukobia, used in combination with other existing antiretroviral therapies, for patients resistant to multiple HIV drugs.

The med, also known as fostemsavir, is the first in a new class called attachment inhibitors. By latching onto the gp120 protein on the surface of HIV, it blocks the virus from entering and infecting immune cells.